Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Carol Moreno, MD, PhD, describes recent advancements in the treatment of CLL

Dr. Moreno, Hematologist, Autonomous University of Barcelona, elaborates on recent advancements in the treatment of chronic lymphocytic leukemia (CLL)

Tags: ASH Conference CoverageLeukemia (includes ALL, AML, APL, CLL, CML, MDS, Myeloproliferative Disorders, Myelofibrosis)

Published: 12 December 2018

Recent Videos: Leukemia (includes ALL, AML, APL, CLL, CML, MDS, Myeloproliferative Disorders, Myelofibrosis)

video

Tanya Siddiqi, MD, elaborates on outcomes from the Phase 2 CAPTIVATE study presented at ASH '19

Dr. Siddiqi, Director, CLL Program, Toni Stephenson Lymphoma Center, Associate Clinical Professor, Department of Hematology, City of Hope, elaborates on ...

video

Tanya Siddiqi, MD, regarding the Transcend-NHL data investigating CAR-T cell therapy in CLL

Dr. Siddiqi, Director, CLL Program, Toni Stephenson Lymphoma Center, Associate Clinical Professor, Department of Hematology, City of Hope, offers impressions ...

video

Richard Stone, MD, describes the landscape of mutations and targeted therapy in AML

Dr. Stone, Physician, Hematologic Oncology, Internal Medicine, Dana-Farber Cancer Institute, describes the landscape of mutations and targeted therapy in acute ...

video

Richard Stone, MD, provides opinion on whether all AML patients should be tested for FLT3 mutations

Dr. Stone, Physician, Hematologic Oncology, Internal Medicine, Dana-Farber Cancer Institute, provides opinion on whether all acute myeloid leukemia (AML) patients ...

video

Richard Stone, MD, elaborates on prognostic factors and the relationship to outcomes in AML

Dr. Stone, Physician, Hematologic Oncology, Internal Medicine, Dana-Farber Cancer Institute, elaborates on prognostic factors and the relationship to outcomes in ...

video

Richard Stone, MD, offers his impression of the landscape for FLT3 inhibition in AML

Dr. Stone, Physician, Hematologic Oncology, Internal Medicine, Dana-Farber Cancer Institute, offers his impression of the landscape for FLT3 inhibition in ...

video

Richard Stone, MD, shares thoughts on current treatment strategies for elderly AML patients

Dr. Stone, Physician, Hematologic Oncology, Internal Medicine, Dana-Farber Cancer Institute, shares thoughts on current treatment strategies for elderly acute myeloid ...

video

Ryan Lynch, MD, on how physicians should be thinking about BTK inhibitors in the treatment of CLL

Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, offers opinion on how physicians should ...

video

Chaitra Ujjani, MD, considers how physicians should be thinking about BTK inhibitors in CLL

Dr. Ujjani, Associate Professor, Seattle Cancer Care Alliance, University of Washington, Fred Hutchinson Cancer Research Center, offers opinion on how ...

video

Jeffrey Sharman, MD, explains how we should be thinking about BTK inhibitors in the treatment of CLL

Dr. Sharman, Director of Hematology Research, US Oncology Research, Willamette Valley Cancer Institute, explains how physicians should be thinking about ...

Related Videos

video-image

Tanya Siddiqi, MD, elaborates on outcomes from the Phase 2 CAPTIVATE study presented at ASH '19

video-image

Tanya Siddiqi, MD, regarding the Transcend-NHL data investigating CAR-T cell therapy in CLL

video-image

Richard Stone, MD, describes the landscape of mutations and targeted therapy in AML

video-image

Richard Stone, MD, provides opinion on whether all AML patients should be tested for FLT3 mutations

video-image

Richard Stone, MD, elaborates on prognostic factors and the relationship to outcomes in AML

video-image

Richard Stone, MD, offers his impression of the landscape for FLT3 inhibition in AML

video-image

Richard Stone, MD, shares thoughts on current treatment strategies for elderly AML patients

video-image

Ryan Lynch, MD, on how physicians should be thinking about BTK inhibitors in the treatment of CLL

video-image

Chaitra Ujjani, MD, considers how physicians should be thinking about BTK inhibitors in CLL

video-image

Jeffrey Sharman, MD, explains how we should be thinking about BTK inhibitors in the treatment of CLL

video-image

Daniel Pollyea, MD, provides opinion on current treatment strategies for elderly AML patients

video-image

Jeffrey Sharman, MD, shares updates from the CLL14 study presented at ASH 2019

video-image

Daniel Pollyea, MD, discusses prognostic factors in acute myeloid leukemia (AML) patients

video-image

Jeffrey Sharman, MD, tells us about the design and outcomes of the Phase 3 ELEVATE TN from ASH 2019

video-image

Daniel Pollyea, MD, discusses the most promising emerging strategies in the management of AML

video-image

Daniel Pollyea, MD, elaborates on the evolving treatment landscape in myelodysplastic syndromes

video-image

Jae H. Park, MD, on incorporating CAR-T cell therapies into acute leukemia treatment algorithms

video-image

Jae H. Park, MD, on the factors associated with improved survival after CD19 CAR-T cell therapy

video-image

Jae H. Park, MD, regarding combination vemurafenib and obinutuzumab in hairy cell leukemia patients

video-image

Chaitra Ujjani, MD, tells us about the results of the Phase 3 ELEVATE TN study in CLL

video-image

Chaitra Ujjani, MD, offers her impression of the Phase 2 CAPTIVATE study in CLL

video-image

Amer Zeidan, MBBS, elaborates on the role of venetoclax in treatment of MDS

video-image

Constantine Tam, MBBS, MD, considers the role of CAR-T cell therapy in chronic lymphocytic leukemia

video-image

Shyamala Navada, MD, MSCR, offers opinion on how the treatment landscape of MDS is evolving

video-image

Constantine Tam, MBBS, MD, offers his impression of the Phase 2 CAPTIVATE study in CLL from ASH '19

video-image

John Burke, MD, offers opinion on how physicians should be thinking about the use of BTK inhibitors

video-image

Courtney DiNardo, MD, provides opinion on current treatment strategies for elderly AML patients

video-image

Courtney DiNardo, MD, describes the targeted therapy landscape in acute myeloid leukemia

video-image

Courtney DiNardo, MD, regarding the evolution of treatment in acute myeloid leukemia

video-image

Courtney DiNardo, MD, considers the role of intensive chemotherapy in newly diagnosed AML

video-image

John Seymour, MBBS, PHD, on whether MRD is a valid endpoint when measuring treatment efficacy in CLL

video-image

John Seymour, MBBS, PHD, elaborates on the updated data from the Phase 3 MURANO trial

video-image

Saro Armenian, DO, MPH, reflects on promising clinical innovations in the management of leukemia

video-image

Saro Armenian, DO, MPH, considers the relevance of bone marrow transplant in leukemia & lymphoma

video-image

Saro Armenian, DO, MPH, on bone marrow transplant survivorship outcomes in AML patients

video-image

James McCloskey, MD, regarding the QUASAR-001 study presented at ASH 2019

video-image

James McCloskey, MD, considers how the role of molecular profiling in AML is changing

video-image

James McCloskey, MD, speculates on the landscape of MDS as a result of data presented at ASH '19

video-image

James McCloskey, MD, shares his impression of the Phase 3 ASCERTAIN trial in MDS

video-image

John Mascarenhas, MD, on JAK inhibitors & combination therapies in myeloproliferative neoplasms

video-image

John Mascarenhas, MD, on the role of molecular analysis in myeloproliferative neoplasms

video-image

Lori Leslie, MD, considers how physicians should be thinking about the use of BTK inhibitors in CLL

video-image

John Mascarenhas, MD, on the individualized management of myeloproliferative neoplasms

video-image

John Mascarenhas, MD, shares outcomes from the MANIFEST study examining CPI-0610 in myelofibrosis

video-image

Catherine Smith, MD, discusses prognostic factors and outcomes in acute myeloid leukemia

video-image

Catherine Smith, MD, offers her overall impression on the changing FLT3 inhibition landscape in AML

video-image

Catherine Smith, MD, on whether all acute myeloid leukemia patients should be tested for FLT3

video-image

Catherine Smith, MD, tells us about the outcomes of the Phase 3 ADMIRAL trial presented at ASH 2019

video-image

Amer Zeidan, MBBS, comments on the influx of investigational oral agents in myeloid malignancies

video-image

Amer Zeidan, MBBS, on his study investigating onvansertib + cytarabine or decitabine in AML

video-image

Paul M. Barr, MD, elaborates on outcomes from the RESONATE trial in relapsed/refractory CLL

video-image

Paul M. Barr, MD, on data from the CLL-14 trial in chronic lymphocytic leukemia

video-image

Paul M. Barr, MD, offers opinion on ibrutinib in 1st line chronic lymphocytic leukemia

video-image

Daniel J. DeAngelo, MD, PhD, comments on how to manage MDS patients ineligible for transplant

video-image

Daniel J. DeAngelo, MD, PhD, considers the implications of the recent wave of approvals in AML

video-image

Daniel J. DeAngelo, MD, PhD, on the significance of the updated data for gilteritinib in AML

video-image

Naiyer Rizvi, MD, explains the role of biomarkers in lung cancer treatment planning

video-image

Daniel J. DeAngelo, MD, PhD, on the latest data involving uproleselan with chemotherapy in AML

video-image

Lori A. Leslie, MD, elaborates on recent outcomes from the CLL14 trial

video-image

Tanya Siddiqi, MD, considers whether data supports the use of CAR-T cell therapy in lymphoma

video-image

Gwen Nichols, MD, regarding the collaboration between the Leukemia and Lymphoma Society and ASH

video-image

Gwen Nichols, MD, on what the Leukemia and Lymphoma Society is doing to help educate members

video-image

Gwen Nichols, MD, offers opinion on the most exciting progress in hematological malignancies

video-image

Gwen Nichols, MD, provides opinion on the most promising clinical presentations from ASH 2019

video-image

Robert Rifkin, MD, FACP, regarding the role of proteasome inhibitors in maintenance therapy for MM

video-image

Frederick Locke, MD, provides his impression of the Transcend-NHL study from ASH 2019

video-image

Frederick Locke, MD, regarding the clinical evidence supporting CAR-T cell therapies in MM

video-image

Nikhil Munshi, MD, tells us about the outcomes of the CARTITUDE-1 study from ASH 2019

video-image

Nikhil Munshi, MD, on the association between MRD and survival outcomes in multiple myeloma

video-image

Nikhil Munshi, MD, considers recent data investigating the bi-specific CAR-T cell therapy

video-image

Richard Stone, MD, on how oral HMA agents may impact the treatment landscape in myeloid malignancies

video-image

Peter M. Voorhees, MD, shares the current thinking regarding treatment algorithms in MM

video-image

Noa Biran, MD, considers the role of BCMA CAR-T cells in the management of multiple myeloma

video-image

Frederick Locke, MD, offers opinion regarding off-the-shelf CAR-T cell therapies

video-image

Noa Biran, MD, provides her impression of the Phase 3 ICARIA-MM study

video-image

Timothy Illidge, MD, PhD, describes the ECHELON-2 data presented at ASH 2019

video-image

Noa Biran, MD, explains how JNJ-4528 differs from other CAR-T products

video-image

Timothy Illidge, MD, PhD, explains the purpose of targeting peripheral t-cell lymphoma

video-image

Noa Biran, MD, tells us about the outcomes of the CARTITUDE-1 study

video-image

Timothy Illidge, MD, PhD, shares the the primary and secondary endpoints of the ECHELON-2 study

video-image

Ryan Lynch, MD, offers his impressions of the Transcend-NHL data presented at ASH 2019

video-image

Timothy Illidge, MD, PhD, on the impact of the ECHELON-2 trial data

video-image

Ryan Lynch, MD, on whether MRD is a valid endpoint when measuring treatment efficacy in CLL

video-image

Ryan Lynch, MD, considers the ideal patient profile for zanubrutinib in RR-MCL

video-image

Christopher Yasenchak, MD, on the most impressive data in the treatment of Hodgkin’s lymphoma

video-image

Ryan Lynch, MD, tells us about the four-year update on the outcomes of the MURANO study

video-image

Chaitra Ujjani, MD, considers the ideal patient profile for zanubrutinib in RR-MCL

video-image

Angela Dispenzieri, MD, speculates on the the clinical impact of the TOURMALINE-AL1 study

video-image

Angela Dispenzieri, MD, elaborates on the outcomes from the TOURMALINE-AL1 study

video-image

Chaitra Ujjani, MD, tells us about Veneto-STOP study presented at ASH 2019

video-image

Angela Dispenzieri, MD, shares the design of the TOURMALINE-AL1 study presented at ASH 2019

video-image

Jeffrey Sharman, MD, on the benefits of zanubrutinib as compared to other BTK inhibitors

video-image

Daniel Pollyea, MD, speculates on how oral HMAs will impact the landscape in myeloid malignancies

video-image

Andre Goy, MD, considers whether off-the-shelf CAR-T cell therapies are becoming a reality

video-image

Andre Goy, MD, on the TRANSCEND-CLL-004 data investigating the use of CAR-T cell therapy DLBCL

video-image

Andre Goy, MD, discusses the three-year survival analysis of the ZUMA-1 study from ASH 2019

video-image

Andre Goy, MD, regarding the ZUMA-2 study investigating anti-CD19 CAR-T cell therapy MCL

video-image

Constantine Tam, MBBS, MD, regarding the patient profile in MCL most suitable for zanubrutinib

video-image

Angela Dispenzieri, MD, expands on the side effects from the TOURMALINE-AL1 study

video-image

Amrita Krishnan, MD, elaborates on BCMA-directed strategies for multiple myeloma patients

video-image

Amrita Krishnan, MD, tells us about the Phase 3 Dreamm-3 study presented at ASH 2019

video-image

David Andorsky, MD, defines RWE and explains how it compliments clinical trial results

video-image

Christopher Yasenchak, MD, on 1st line brentuximab vedotin + nivolumab in Hodgkin’s lymphoma

video-image

David Andorsky, MD, provides examples of how RWE has impacted the oncology community

video-image

Christopher Yasenchak, MD, tells us about the patient profile most suited for zanubrutinib in MCL

video-image

David Andorsky, MD, on the results of his RWE study investigating idelalisib in follicular lymphoma

video-image

Amrita Krishnan, MD, tells us about the outcomes of the CARTITUDE-1 study presented at ASH 2019

video-image

David Andorsky, MD, discusses the implications of real-world evidence for oncologists

video-image

Amrita Krishnan, MD, tells us about the results of the Phase 1 study investigating CC-93269 in MM

video-image

James Essell, MD, offers opinion on the future of off-the-shelf CAR-T cell therapy

video-image

Amer Zeidan, MBBS, considers RWE in older patients with acute myeloid malignancies

video-image

James Essell, MD, regarding off-the-shelf CAR NK cell therapy in treating B-cell malignancies

video-image

Amer Zeidan, MBBS, speculates on the role of immune checkpoint blockades in myeloid malignancies

video-image

James Essell, MD, offers his impression the data investigating the bi-specific CAR-T cell therapy

video-image

James Essell, MD, discusses the integration of stem cell transplantation in the treatment of myeloma

video-image

Amer Zeidan, MBBS, on the role of oral therapies in the treatment of myeloid malignancies

video-image

Peter M. Voorhees, MD, explains how daratumumab is changing the way MM patients are treated today

video-image

Constantine Tam, MBBS, MD, tells us about the Phase 2 CAPTIVATE study presented at ASH 2019

video-image

Peter M. Voorhees, MD, summarizes the outcomes of the Phase 2 Griffin study in newly diagnosed MM

video-image

Constantine Tam, MBBS, MD, compares the benefits of zanubrutinib to other BTK inhibitors

video-image

Shyamala Navada, MD, MSCR, discusses the treatment of elderly patients with myeloid malignancies

video-image

Constantine Tam, MBBS, MD, regarding the data that lead to the recent FDA approval of zanubrutinib

video-image

Sattva Neelapu, MD, tells us about the results of the ZUMA-1 study in DLBCL presented at ASH 2019

video-image

Sattva Neelapu, MD, considers whether off-the-shelf CAR-T cell therapy is becoming a reality

video-image

Sattva Neelapu, MD, on the role of CAR NK cell therapy in the treatment of B-cell malignancies

video-image

Shyamala Navada, MD, MSCR, on how oral therapies will impact the treatment of myeloid malignancies

video-image

John Burke, MD, regarding tafasitamab or tafasitamab + lenalidomide in addition to R-CHOP in DLBCL

video-image

Robert Rifkin, MD, FACP, on whether medical oncologists are embracing therapeutic biosimilars

video-image

John Burke, MD, outlines the patient profile best suited for zanubrutinib in relapsed/refractory MCL

video-image

Robert Rifkin, MD, FACP, on the role of daratumumab as maintenance therapy in the management of MM

video-image

Luciano J. Costa, MD, PhD, offers opinion on whether MRD tests can help guide treatment decisions

video-image

Robert Rifkin, MD, FACP, offers opinion on the most promising studies in MM presented at ASH 2019

video-image

Luciano J. Costa, MD, PhD, explains how academic and community oncologists can utilize MRD tests

video-image

Jasmine Zain, MD, shares outcomes from the PRIMO study investigating duvelisib in PTCL

video-image

Jasmine Zain, MD, tells us about the novel approaches in development for the treatment of PTCL

video-image

Jasmine Zain, MD, discusses the most impressive studies in PTCL presented at ASH 2019

video-image

Jasmine Zain, MD, considers how peripheral T-cell lymphoma therapy has evolved in recent years

video-image

Max Topp, MD, on whether a risk management plan exists to help reduce toxicity of CAR-T cell therapy

video-image

Bruce Feinberg, DO, elaborates on how oncologists are utilizing real-world evidence today

video-image

Bruce Feinberg, DO, provides examples of how RWE has impacted decision-making in oncology

video-image

Bruce Feinberg, DO, defines and explains the role of real-world evidence

video-image

Kylee Martens, MD, compares rasburicase versus allopurinol in patients with hyperuricemia

video-image

Michael Wang, MD, regarding the pivotal clinical data that lead to the FDA approval of zanubrutinib

video-image

Michael Wang, MD, speculates on therapies for front-line and relapsed mantle cell lymphoma

video-image

Michael Wang, MD, on the distinct advantages of zanubrutinib in the management of lymphoma

video-image

Kylee Martens, MD, on the role of rasburicase in managing TLS in patients with renal dysfunction

video-image

Kylee Martens, MD, on those patient types more suited for treatment with rasburicase vs. allopurinol

video-image

Max Topp, MD, shares the long-term results of the ZUMA-1 trial presented at ASH 2019

video-image

Kylee Martens, MD, considers whether there are certain patient types more prone to TLS

video-image

Luciano J. Costa, MD, PhD, on whether minimal residual disease can be used to predict outcomes

video-image

Robert Rifkin, MD, FACP, tells us about the outcomes of the LYRA study presented at ASH 2019

video-image

Luciano J. Costa, MD, PhD, on how measurement of MRD is evolving as an endpoint in clinical trials

video-image

Catherine Diefenbach, MD, explains how combination therapies are evolving in follicular lymphoma

video-image

Joseph Alvarnas, MD, on seeking creative solutions to provide proper access to innovative therapy

video-image

Joseph Alvarnas, MD, on the challenges facing cancer centers when delivering innovative therapies

video-image

Catherine Diefenbach, MD, regarding the unmet needs in the management of follicular lymphoma

video-image

Michael Wang, MD, shares details from the ZUMA-2 trial in mantle cell lymphoma presented at ASH 2019

video-image

Joseph Alvarnas, MD, regarding CAR-T cell therapy in an era of value-based care

video-image

Catherine Diefenbach, MD, on the recent data investigating obinutuzumab in follicular lymphoma

video-image

Andrew Cowan, MD, elaborates on the role of isatuximab in the management of multiple myeloma

video-image

Joseph Alvarnas, MD, on how to responsibly integrate clinical innovations into treatment algorithms

video-image

Michael Jain, MD, offers his opinion on off-the-shelf CAR-T cell therapy

video-image

Michael Jain, MD, shares the outcomes of the US CAR-T Cell Consortium study from ASH 2019

video-image

Andrew Cowan, MD, on the most promising clinical data in multiple myeloma presented at ASH 2019

video-image

Michael Jain, MD, discusses how population-based outcomes in B-cell lymphomas are changing

video-image

Andrew Cowan, MD, provides an overview of the use of CAR-T cell therapy in multiple myeloma

video-image

Michael Jain, MD, offers perspective on the latest treatment trends for aggressive lymphomas

video-image

Andrew Cowan, MD, discusses the role of human BCMA CAR-T cells in the management of multiple myeloma

video-image

Michael Jain, MD, regarding CAR-natural killer (NK) cell therapy

video-image

Lori Leslie, MD, on real-world evidence regarding CAR-T cell therapy in lymphoma

video-image

Lori Leslie, MD, offers perspective on the role of umbralisib in relapsed/refractory lymphoma

video-image

Lori Leslie, MD, considers the use of zanubrutinib in relapsed/refractory mantle cell lymphoma

video-image

Lori Leslie, MD, offers her perspective on the latest treatment trends in aggressive lymphomas

video-image

Joshua Richter, MD, on the Phase 3 ICARIA-MM study from the 61st ASH Annual Meeting and Exposition

video-image

Joshua Richter, MD, discusses the data investigating iberdomide presented at ASH 2019

video-image

Joshua Richter, MD, provides opinion on the role of BCMA CAR-T cells in the management of MM

video-image

Parameswaran Hari, MD, MRCP, offers his impression of the Phase 3 ICARIA-MM trial from ASH 2019

video-image

Joshua Richter, MD, regarding the Phase 3 CANDOR study in relapsed/refractory multiple myeloma

video-image

Parameswaran Hari, MD, MRCP, on novel combination treatment options & sequencing strategies in MM

video-image

Parameswaran Hari, MD, MRCP, considers the role of stem cell transplantation in myeloma

video-image

Parameswaran Hari, MD, MRCP, tells us about the design & outcomes of the STORM and Mammoth studies

video-image

Deepu Madduri, MD, explains how JNJ-4528 differs from other CAR-T products

video-image

Leslie Popplewell, MD, summarizes the role of checkpoint inhibitors in the treatment of lymphomas

video-image

Leslie Popplewell, MD, on the role of CAR-T cell therapy in aggressive B-cell lymphomas

video-image

Leslie Popplewell, MD, considers the use of CAR-T cell therapies in aggressive B-cell lymphomas

video-image

Leslie Popplewell, MD, considers whether there is sufficient evidence supporting bridging therapy

video-image

Deepu Madduri, MD, on how CAR-T cell therapy plays a role in the management of multiple myeloma

video-image

Leslie Popplewell, MD, offers opinion on the next frontier in the development of CAR-T treatment

video-image

Deepu Madduri, MD, elaborates on the outcomes of the CARTITUDE-1 study